Group items tagged

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

The 2017 CDC STD Surveillance Report documented continued steep and sustained increases in the three reportable STDs - gonorrhea, chlamydia and syphilis. Congenital syphilis rates reached a 20-year high in 2017. Healthcare providers and health systems remain at the forefront of the battle against STDs. Provider education, technical assistance, and clinical capacity building are critical pieces for a foundation of comprehensive STD clinical prevention in healthcare settings. A dynamic and complex healthcare landscape demands innovative methods to reach both clinicians and healthcare settings from a variety of sectors throughout the U.S in order to meet the goal of optimal STD clinical prevention implementation in the clinical care setting. The purpose of this NOFO is to support The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC). This network is charged with improving the capacity of healthcare professionals, clinical sites and healthcare systems to employ state-of-the-art knowledge to diagnose, manage, treat and counsel individuals with and at-risk for STDs in order to reduce STD morbidity and improve sexual health on an individual, local and national level. This NOFO supports the following broad strategies : Component A Regional Centers: A1 (Core) - assess training needs and service gaps to inform the development and delivery of comprehensive STD clinical prevention T/TA for providers serving priority populations; A2 (Focus Activity) - pr

The Patient-Centered Outcomes Research Institute helps people make informed healthcare decisions and improves healthcare delivery and outcomes by producing and promoting high-integrity evidence-based information that comes from research guided by patients, caregivers, and the broader healthcare community. PCORI currently is inviting Letters of Inquiry for its Eugene Washington PCORI Engagement Awards program. Through the program, the institute will award grants of up to $250,000 over two years to projects that encourage active integration of patients, caregivers, clinicians, and other healthcare stakeholders as integral members of the patient-centered outcomes research/clinical effectiveness research (PCOR/CER) enterprise.

The purpose of this FOA is to expand the number of CDC Prevention Epicenters to translate basic, epidemiologic and technologic discoveries into new strategies for preventing healthcare-associated transmission of Ebola and/or infectious pathogens (viral or bacterial) that can be spread by mechanisms similar to Ebola. This might include, but is not limited to, project proposals that focus on the effectiveness of personal protective equipment against such pathogens, healthcare worker self-contamination with pathogens, or the role of the healthcare environment in pathogen transmission.

to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving one or more health disparity populations during Phase I and Phase II.

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups. PCORI's multi-stakeholder panels have identified 16 high-priority topics and research questions. (See PFA Appendix for list.) PCORI will give first consideration to applications that directly address one or more of the 16 PCORI identified topics. Note that PCORI is open to receiving and reviewing LOIs for studies on investigator-initiated CER questions as well. Note that this funding program does not support applications to conduct cost-effectiveness analyses, systematic reviews (with or without meta-analyses), or developing or evaluating shared decision-making or decision-support tools. In general, PCORI will not cover costs for interventions that are being compared in the proposed study. (See Appendix 3 in the Application Guidelines for details.) This announcement is a collaborative effort of PCORI's Comparative Clinical Effectiveness Research, Communication and Dissemination Research, Improving Healthcare Systems, and Addressing Disparities research programs.

The purpose of this funding opportunity is to conduct activities to promote and support vaccination services within the pharmacy setting. Activities include, but are not limited to: - Education/Outreach to pharmacists about current pediatric, adolescent, and adult immunization recommendations and proper vaccine administration - Facilitation of communication and exchange of information between pharmacists and providers and public health programs -Quality Improvement efforts -Improved immunization documentation through use of immunization information systems and data sharing -Coordination with public health preparedness and immunization programs to establish formalized agreements for pandemic vaccine program readiness and response By the end of the project, the awardee is expected to disseminate and promote best practices/successes to a national audience of healthcare providers, including both pharmacists and other healthcare providers.

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.

The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and other community collaborations is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.

GSK Consumer Healthcare currently is the largest global marketer of nicotine replacement therapies (NRT) for smoking cessation. We serve patients in over 20 countries, including the US, Canada, across Europe, and Australia.   GSK Consumer Healthcare strives to transform the future of self-care. We hope to leverage the wisdom of experts within the fields of nicotine and tobacco research to identify areas of critical and emerging unmet needs within the tobacco cessation and reduction space and collaborate with key scientific partners to help deliver upon them.

What we will consider funding: Innovative ideas for improving measurement of coverage and equity data for use by program staff and managers. Specifically, their ability to collect and deliver the right data at the right time to the appropriate audiences would benefit from: Incorporating advances in technology to support decision makers in planning and executing program strategies Integration of immunization data systems, as well as the ability to address data use demands from multiple stakeholders. Enabling a culture that supports data quality and use e.g. provides feedback on data at multiple levels. Alignment of incentives to promote reporting of accurate data above coverage estimates. Innovations in process efficiency toward improved service delivery. These may stem from lean healthcare, or other approaches, but should have the end goal of improving the experience of healthcare workers, caregivers, or both.

The Doctors Company Foundation was created in 2008 by the Doctors Company, the nation's largest insurer of medical professional liability for physicians, surgeons, and other health professionals. The purpose of the foundation is to support patient safety education for healthcare professionals in training and in practice, as well as patient safety research with clinically useful applications. To advance this mission, the foundation is accepting applications for research and education programs and projects designed to enhance patient safety. Grant amounts will be determined on an individual basis based on project budget and availability of funds. The foundation does not support clinical research projects primarily involving the provision of medical support services to patients. Construction projects and the purchase of equipment will not be funded. While general funding for medical meetings and conferences will not be considered, support for invited speakers when the principal focus of their presentation is on patient safety and support for the attendance of healthcare professionals in training at patient safety conferences will be considered.

This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and healthcare institutions.   

Ohio is home to approximately 26,000 individuals living with paralysis as a result of a Spinal Cord Injury (SCI). According to the National SCI Statistical Center 66% of those individuals remain unemployed with each expected to manage lifetime healthcare costs of $1-3M. This represents a significant cost to the state and also imposes a severe burden on the quality of life for those living with this impairment. While there is research in pursuit of improved treatments to ameliorate the effects of paralysis, the field is significantly underfunded relative to similarly sized patient populations or disease with similar lifetime healthcare costs. While the scientific disciplines of neuroscience and biomedical engineering are making progress toward the development of new treatments, there is a lack of systematic and especially localized effort to guide these advances representative of the various stakeholders. The research funded through this process is specifically targeted to advance and accelerate the development of innovative treatments, product innovation and rehabilitative efforts that lead to the functional improvement of people living with spinal cord injuries. Research topics may include, but are not limited to, discovery science, pharmaceutical development, medical device design and implementation, and the development of novel rehabilitative approaches and techniques.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of gastrointestinal tract. In 2015, approximately three million US adults reported having a diagnosis of IBD and the estimated number has increased greatly from 1.8 million since 1999. While the exact cause is unknown, the severity and progression of the disease largely impacts the patients’ quality of life and imposes huge financial burden to the US healthcare system. The purpose of this announcement is to 1) establish a new IBD registry to estimate incidence of IBD in the adult and pediatric populations and extrapolate to the US population; 2) describe the natural history and outcomes of IBD; 3) determine racial/ethnic variation in the detection and management of IBD; and 4) identify evidence-based strategies to improve disease outcomes. The results are anticipated to enhance understanding of the impact of IBD on the overall health of affected persons and the impact of various clinical practices and healthcare delivery approaches on the disease outcomes.

The Robert Wood Johnson Foundation Health Policy Fellows program is designed to provide a comprehensive fellowship experience at the nexus of health science, policy, and politics in Washington, D.C. The program provides an opportunity for exceptional mid-career health professionals and behavioral and social scientists with an interest in health and healthcare policy. Fellows participate in the policy process at the federal level and use that leadership experience to improve health, health care, and health policy. Exceptional candidates from academic faculties and nonprofit healthcare organizations are encouraged to apply. Applicants may have backgrounds in the disciplines of allied health professions, biomedical sciences, dentistry, economics or other social sciences, health services organization and administration, medicine, nursing, public health, social and behavioral health, or health law. Applicants must be U.S. citizens or permanent residents. Up to six grants of a maximum of $165,000 will be made in 2018. Each fellow will receive up to $104,000 for their stay in Washington (September 1, 2018, through August 31, 2019) in salary, plus fringe benefits or a fellowship stipend.